Skip to main content
SpringerLink
Log in

CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Postsynaptic dopamine-cholecystokinin (CCK) interactions in the nucleus accumbens were studied in two behavioral preparations of DA receptor supersensitivity: chronic-neuroleptic treated and 6-hydroxydopamine (6-OHDA) denervated rats. Subcutaneous (SC) injections of apomorphine (APO; 0.15 mg/kg) in experiment 1 produced marked hyperlocomotion in rats following 12 days of pretreatment with cis-[Z]-flupenthixol (2 mg/kg; twice per day). Bilateral intra-accumbens (N.Acc.) microinjections of CCK-8 (2 ng and 2 μg) reliably reduced APO-stimulated hyperlocomotion. An intermediate CCK dose (20 ng) was without effect. No change in APO responsivity following chronic vehicle treatment was observed and the baseline APO response was not altered by CCK at any dose. Denervation of mesolimbic dopamine (DA) terminals by intra-N.Acc. injections of 6-hydroxydopamine (6-OHDA; 8 μg/side) in experiment 2 similarly resulted in intense locomotor hyperactivity after APO stimulation (0.1 mg/kg; SC). Bilateral intra-N.Acc. injections of CCK-8 (1, 10, 100 ng, and 1 μg) significantly attenuated the supersensitive locomotor response to APO. As in experiment 1, CCK produced “biphasic” dose-response effects with strong attenuation that persisted throughout the entire 60-min test at both high (1 μg) and low (1 ng) doses. Intermediate CCK doses (10 and 100 ng) produced only shortterm reductions in activity. Hypomotility induced by APO in SHAM-lesioned rats was not effectively reversed by CCK treatments. CCK had no effect on unstimulated baseline locomotor activity in either 6-OHDA or SHAM-lesioned rats. These results provide further evidence that CCK-8 modulates mesolimbic DA activity by functionally opposing the postsynaptic effects of DA in the region of the nucleus accumbens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Agnati LF, Fuxe K (1983) Subcortical limbic 3H-N-propylnorapomorphine binding sites are markedly modulated by cholecystokinin-8 in vitro. Biosci Rep 3:1101–1105

    Google Scholar 

  • Agnati LF, Fuxe K, Giardino L, Calza L, Zoli M, Battistini F, Benfenati F, Vanderhaegen J-J, Guidolin D, Ruggeri M, Goldstein M (1985) Evidence for cholecystokinin-dopamine receptor interactions in the central nervous system of the adult and old rat. Ann NY Acad Sci 448:315–333

    Google Scholar 

  • Blaha CD, Phillips AG, Lane RF (1987) Reversal by cholecystokinin of apomorphine-induced inhibition of dopamine release in the nucleus accumbens of the rat. Regul Pept 17:301–310

    Google Scholar 

  • Burt DR, Creese I, Snyder SH (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 196:326–328

    Google Scholar 

  • Chang RSL, Lotti VJ, Martin GE, Chen TB (1983) Increase in brain 125I-cholecystokinin (CCK) receptor binding following chronic haloperidol treatment, intracisternal 6-hydroxydopamine or ventral tegmental lesions. Life Sci 32:871–878

    Google Scholar 

  • Cohen SL, Knight M, Tamminga CA, Chase T (1982) Cholecystokinin-octapeptide effects on conditioned avoidance behavior, stereotypy and catalepsy. Eur J Pharmacol 83:213–222

    Google Scholar 

  • Crawley JN, Hommer DW, Skirbol LR (1985a) Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat. Brain Res 335:337–341

    Google Scholar 

  • Crawley JN, Stivers JA, Blumstein LK, Paul SM (1985b) Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence. J Neurosci 5:1972–1983

    Google Scholar 

  • Cross AJ, Crow TJ, Owen F (1981) 3H-Flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology 74:122–124

    Google Scholar 

  • DeFrance JF, Sikes RW, Chronister RB (1984) The effects of CCK-8 in the nucleus accumbens. Peptides 5:1–6

    Google Scholar 

  • Ellinwood HE Jr, Rockwell WJK, Wagoner N (1983) A caeruleinsensitive potentiation of the behavioral effects of apomorphine by dibutyryl-c-AMP. Pharmacol Biochem Behav 19:969–971

    Google Scholar 

  • Fekete M, Szabo A, Balazs M, Penke B, Telegdy G (1981) Effects of intraventricular administration of cholecystokinin octapeptide sulfate ester and unsulfated cholecystokinin octapeptide on active avoidance and conditioned feeding behavior of rats. Acta Physiol Acad Sci Hung 58:39–45

    Google Scholar 

  • Fekete M, Rentzsch A, Schwarzberg H, Telegdy G (1983) Effects of cholecystokinin on self-stimulation behavior in rats. Eur J Pharmacol 91:77–82

    Google Scholar 

  • Frey P (1983) Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment. Eur J Pharmacol 95:87–92

    Google Scholar 

  • Gysling K, Beinfeld MC (1984) Failure of chronic haloperidol treatment to alter levels of cholecystokinin in the rat brain striatum and olfactory tubercle-nucleus accumbens area. Neuropeptides 4:421–423

    Google Scholar 

  • Hökfelt T, Rehfeld JF, Skirbol L, Ivemark B, Goldstein M, Markey K (1980a) Evidence for coexistence of dopamine and CCK in meso-limbic neurons. Nature 238:476–478

    Google Scholar 

  • Hökfelt T, Skirbol L, Rehfeld JF, Goldstein M, Markey K, Dann O (1980b) A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contain cholecystokinin-like peptide. Neuroscience 5:2093–2124

    Google Scholar 

  • Hommer DW, Skirbol LR (1983) Cholecystokinin-like peptides potentiate apomorphine-induced inhibition of dopamine neurons. Eur J Pharmacol 91:151–152

    Google Scholar 

  • Hommer DW, Pickar D, Roy A, Ninan P, Boronow J, Paul SM (1984) The effects of ceruletide in schizophrenia. Arch Gen Psychiatry 41:617–619

    Google Scholar 

  • Itoh S, Katsuura G (1981) Suppressive action of cholecystokinin octapeptide on the behavioral effects of l-dopa in the rat. Eur J Pharmacol 75:313–316

    Google Scholar 

  • Joyce EM, Koob GF (1981) Amphetamine-, scopolamine-, and caffeine-induced locomotor activity following 6-hydroxydopamine lesions of the mesolimbic dopamine systems. Psychopharmacology 73:311–313

    Google Scholar 

  • Katsuura G, Itoh S, Rehfeld JF (1984) Effects of cholecystokinin on apomorphine-induced changes of motility in rats. Neuropharmacology 23:731–734

    Google Scholar 

  • Katsuura G, Itoh S, Hsiao S (1985) Specificity of nucleus accumbens to activities related to cholecystokinin in rats. Peptides 6:91–96

    Google Scholar 

  • Kelly PH, Roberts DCS (1983) Effects of amphetamine and apomorphine on locomotor activity after 6-OHDA and electrolytic lesions of the nucleus accumbens septi. Pharmacol Biochem Behav 19:137–143

    Google Scholar 

  • Kelly PH, Seviour PW, Iversen SD (1975) Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94:507–522

    Google Scholar 

  • Lee T, Seeman P (1980) Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am J Psychiatry 137:191–197

    Google Scholar 

  • Lotstra F, Verbanck P, Mendlewicz J, Vanderhagen JJ (1984) No evidence of antipsychotic effects of caerulein in schizophrenic patients free of neuroleptics: a double-blind crossover study. Biol Psychiatry 19:877–882

    Google Scholar 

  • Matsubara K, Matsushita A (1984) Long-lasting reduction of amphetamine-induced hyperactivity in rats after combined administration of caerulein with haloperidol. Eur J Pharmacol 101:157–158

    Google Scholar 

  • Matsushita A, Itoh S (1982) Pharmacological properties of caerulein, a CCK-8 analogous peptide. Proc World Psychiatric Association, pp 170–173

  • Möller-Nielsen I, Fjalland B, Pedersen V, Nymark M (1974) Pharmacology of neuroleptics upon repeated administration. Psychopharmacologia 34:95–104

    Google Scholar 

  • Moroji T, Watanabe N, Aoki N, Itoh S (1982) Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide in schizophrenia. Int Pharmacopsychiatry 17:255–273

    Google Scholar 

  • Nair NPV, Bloom DM, Nestoros JN, Schwartz G (1983) Therapeutic efficacy of cholecystocinin in neuroleptic-resistant schizophrenic subjects. Pharmacol Bull 19:134–136

    Google Scholar 

  • Nair NP, Bloom DM, Debonnel G, Schwartz G, Mosticyan S (1984) Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 8:711–714

    Google Scholar 

  • Nair NPV, Lal S, Bloom DM (1985) Cholecystokinin peptides, dopamine and schizophrenia — a review. Prog Neuropsychopharmacol Biol Psychiatry 9:515–524

    Google Scholar 

  • Oldendorf WH (1981) Blood-brain barrier permeability to peptides: pitfalls in measurement. Peptides [Suppl] 2:109–111

    Google Scholar 

  • Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic Press, New York

    Google Scholar 

  • Pellegrino LJ, Pellegrino AS, Cushman AJ (1979) A stereotaxic atlas of the rat brain. Plenum Press, New York

    Google Scholar 

  • Peselow E, Angrist B, Sudilovsky A, Corwin J, Siekierski J, Trent F, Rotrosen J (1987) Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia. Psychopharmacology 91:80–84

    Google Scholar 

  • Reisine TD, Rosner M, Spokes E, Iversen LL, Yamamura HI (1980) Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue. Adv Biochem Psychopharmacol 21:443–450

    Google Scholar 

  • Ruggeri M, Ungerstedt U, Agnati LF, Mutt V, Harfstrand A, Fuxe K (1987) Effects of cholecystokinin peptides and neurotensin on dopamine release and metabolism in the rostral and caudal part of the nucleus accumbens using intracerebral dialysis in the anesthetized rat. Neurochem Int 10:509–520

    Google Scholar 

  • Schneider LH, Alpert JE, Iversen SD (1983) CCK-8 modulation of mesolimbic dopamine: antagonism of amphetamine-stimulated behaviors. Peptides 4:749–753

    Google Scholar 

  • Skirbol LR, Grace AA, Hommer DW, Rehfeld J, Goldstein M, Hokfelt T, Bunney BS (1981) Peptide monoamine coexistence: studies of the action of a cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons. Neuroscience 6:2111–2124

    Google Scholar 

  • Tamminga CA, Littman RL, Alphs LD, Chase TN, Thaker GK, Wagman AM (1986) Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. Psychopharmacology 88:387–391

    Google Scholar 

  • Tarsy D, Baldessarini BJ (1973) Pharmacologically induced behavioural supersensitivity to apomorphine. Nature New Biol 245:262–263

    Google Scholar 

  • Ungerstedt U (1971a) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand [Suppl 367] 83:69–93

    Google Scholar 

  • Ungerstedt U (1971b) Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand [Suppl 367] 83:49–68

    Google Scholar 

  • Vaccarino FJ, Koob GF (1984) Microinjections of nanogram amounts of sulfated cholecystokinin octapeptide into the rat nucleus accumbens attenuates brain stimulation reward. Neurosci Lett 52:61–66

    Google Scholar 

  • Vaccarino F, Rankin J (1987) Opposite effects of rostral and caudal accumbens CCK microinjections on amphetamine-induced locomotion. Soc Neurosci Abstr 13:1273

    Google Scholar 

  • Van Ree JM, Gaffori O, de Wied D (1983) In rats, the behavioral profile of CCK-8 related peptides resembles that of antipsychotic agents. Eur J Pharmacol 93:63–78

    Google Scholar 

  • Van Ree JM, Verhoeven WM, de Wied D (1987) Animal and clinical research on neuropeptides and schizophrenia. Prog Brain Res 72:249–267

    Google Scholar 

  • Voigt MM, Wang RY, Westfall TC (1988) The effects of cholecystokinin on the in vitro release of newly synthesized [3H]dopamine from the nucleus accumbens of the rat. J Neurosci 5:2744–2749

    Google Scholar 

  • Wang RY, Hu X-T (1986) Does cholecystokinin potentiate dopamine action in the nucleus accumbens? Brain Res 380:363–367

    Google Scholar 

  • White FJ, Wang RJ (1984) Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons. Brain Res 300:161–166

    Google Scholar 

  • Weiss F, Tanzer DJ, Ettenberg A (1988) Opposite actions of CCK-8 on amphetamine-induced hyperlocomotion and stereotypy following intracerebroventricular and intra-accumbens injections in rats. Pharmacol Biochem Behav 30:309–317

    Google Scholar 

  • Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussole EP, Ravert HT, Wilson AA, Toung JKT, Malat J, Williams JA, O'Tuama LA, Snyder SH, Kuhar MJ, Gjedde A (1986) Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234:1558–1563

    Google Scholar 

  • Zetler G (1985) Antistereotypic effects of cholecystokinin octapeptide (CCK-8), ceruletide and related peptides on apomorphineinduced gnawing in sensitized mice. Neuropharmacology 24:251–259

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Experimental Medicine, Division of Preclinical Neuroscience and Endocrinology, Research Institute of Scripps Clinic, 10666 North Torrey Pines Road, 92037, La Jolla, CA, USA

    F. Weiss & G. F. Koob

  2. Department of Psychology, University of California, 93016, Santa Barbara, CA, USA

    A. Ettenberg

Authors
  1. F. Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Ettenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. F. Koob
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weiss, F., Ettenberg, A. & Koob, G.F. CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats. Psychopharmacology 99, 409–415 (1989). https://doi.org/10.1007/BF00445568

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00445568

Key words

Search

Navigation